Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03802227 · ClinicalTrials.gov registry record · Phase 1
A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.
A Phase 1 study, sponsored by Nektar Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03802227 is a Phase 1 study that was terminated before completion, run by Nektar Therapeutics. The registered enrollment target is 8 participants.
The verdict
NCT03802227, a Phase 1 study, was terminated before completion, sponsored by Nektar Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effect of NKTR-181 on brain activity in healthy, non-physically dependent recreational opioid users. This study will last about 88 days for each participant.
Interventions
- DRUG Oxycodone IR
- DRUG NKTR-181
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-10-22 |
| Est. Completion | 2020-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03802227
The ClinicalTrials.gov registry entry for NCT03802227 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oxycodone IR is the first listed.
NCT03802227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03802227 about?
NCT03802227 is a clinical study titled "A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.". The main purpose of this study is to evaluate the effect of NKTR-181 on brain activity in healthy, non-physically dependent recreational opioid users. This study will last about 88 days for each participant.
What is the current status of trial NCT03802227?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-10-22. Estimated completion is 2020-01-03.
What interventions are being tested in trial NCT03802227?
The interventions under investigation include: Oxycodone IR (DRUG), NKTR-181 (DRUG).
Who is sponsoring clinical trial NCT03802227?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.